Bioengineering professor Karen Christman's novel injectable hydrogel, which is designed to repair damaged cardiac tissue next a pump attack, has been licensed to San Diego-based startup Ventrix, Inc, which is planning the commencement human clinical trials of the technology. Christman is a co-founder of Ventrix.
In a 2013 study published inwards Science Translational Medicine, Christman reported the semi-solid, porous gel encourages cells to repopulate areas of damaged cardiac tissue as well as to save pump function. The hydrogel forms a scaffold to repair the tissue as well as increases cardiac muscle.
You tin acquire to a greater extent than nearly this engineering at Research Expo on Apr 17, where Christman is 1 of 6 faculty speakers. In the meantime, sentry our video study above. Wang, an M.D./Ph.D. pupil inwards bioengineering, volition introduce a poster explaining her question on how the hydrogel plant to rebuild tissue inwards damaged hearts.